title: COMBINED VITRECTOMY AND INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of combining intravitreal dexamethasone implantation (Ozurdex) with pars plana vitrectomy (PPV).
  
  
  METHODS
  A retrospective review was conducted on cases where Ozurdex injection was performed in the operating room in conjunction with pars plana vitrectomy. Our primary outcome measure was the presence of surgical complications in the perioperative and 3-month postoperative window. We also measured visual acuity, intraocular pressure (IOP), and macular edema at baseline, one, and 3 months after surgery.
  
  
  RESULTS
  Fifteen eyes in 14 cases were reviewed. There were no complications intraoperatively or at 1-month postoperatively. Two patients (2 eyes) with prior retinal detachment developed proliferative vitreoretinopathy and redetachment at 3 months. Visual acuity improved in 7 of 15 eyes, and an average improvement of 2 lines was achieved for the entire cohort. There was no overall change in intraocular pressure although 1 patient developed an increase in intraocular pressure >5 mmHg. Five of 9 patients with baseline macular edema experienced improvement or resolution at 3 months.
  
  
  CONCLUSIONS
  Intraoperative Ozurdex in combination with PPV may be safe and effective in treating macular edema caused by many different underlying diseases.
authors.affiliation: *The Bernard and Shirlee Brown Glaucoma Laboratory, Departments of Ophthalmology, Pathology and Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, New York, New York; †Omics Laboratory, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa; ‡Vitreoretinal Service, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa; §Retina Consultants of Southern California, Redlands, California; and ¶VitreoRetinal Surgery, Minneapolis, Minnesota.
authors.forename: Andrew
authors.initials: A
authors.lastname: Zheng
authors.forename: Eric K
authors.initials: EK
authors.lastname: Chin
authors.forename: David R P
authors.initials: DR
authors.lastname: Almeida
authors.forename: Stephen H
authors.initials: SH
authors.lastname: Tsang
authors.forename: Vinit B
authors.initials: VB
authors.lastname: Mahajan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D015866:Uveitis, Posterior / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy; D014792:Visual Acuity / Q000502:physiology; D014821:Vitrectomy / Q000379:methods*; D057135:Wet Macular Degeneration / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone